OBJECTIVES : Adherence to treatment against hepatitis C virus (HCV) can condition its effectiveness in real clinical practice. However, no previous large studies has been released about adherence to direct-acting antivirals (DAAs). The aim of this study is to describe patient adherence to DAAs and to identify patient, drug o virus factors associated with it.

METHODS : Longitudinal historical cohort study for 2 years. Study protocol approved by the Clinical Research Ethics Committee; all patients signed informed consent for participation. Data anonymized source was a local Intelligent Monitoring Information System (SiMON) designed for the clinical follow-up of HCV patients. 100% patients included (no sample selection; no exclusion criteria). Measurement of adherence was the continuous measure of medication acquisition (CMA). Variable analysis through business intelligence techniques (Microsoft. “Integration Services”©; v2008). Statistical analysis: parametric test “t-Student” or “chi square-Pearson” for 95% confidence level.

RESULTS : CONCLUSIONS : Very high adherence to DAAs has been observed, superior to that with interferon based treatments. None of the analyzed basal factors has a significant influence on adherence so that no subgroup of patients requires a special follow-up of the adherence that could condition the effectiveness of the DAAs in the real clinical practice.